CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 81 enrolled
Drug / intervention
Pazopanib +1 moredrug
Likely dose
Pazopanib 800 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01323400
NCT01323400Phase 2Completed
CompareCT.gov

A Phase II Randomized Multicentre Study Evaluating the Efficacy of Pazopanib+Best Supportive Care (BSC) Versus BSC Alone in Metastatic and/or Locally Advanced Unresectable GIST, Resistant to Imatinib and Sunitinib

Centre Leon Berard·interventional·Posted Mar 25, 2011·Updated Feb 25, 2016

In Brief

A Phase 2 clinical trial evaluating Pazopanib and Best supportive care for GIST. Completed, enrolled 81 participants across 13 sites.

Detailed Summary

The purpose of this study is to evaluate the antitumor activity of pazopanib in patients with metastatic and/or locally advanced unresectable Gastrointestinal Stromal Tumors (GIST) resistant to imatinib and sunitinib. This is a phase II, randomized, multicentre study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGIST
CountriesFrance
CollaboratorsGlaxoSmithKline

Timeline

Phase 2CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMar 25, 2011
Enrollment StartMar 1, 2011
Primary CompletionApr 1, 2014
Study CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 15.3 years ago

Interventions

Pazopanibdrug

Pazopanib is administered orally at 800 mg/day (one dose every morning). A dose modification is possible in case of documented toxicity, according to specific algorithms.

Best supportive careother

Best supportive care according to the investigator's judgment (chemotherapy, immunotherapy, hormone therapy are not allowed). Non-targeted radiation therapy is tolerated, as antalgic strategy. Surgery is tolerated in case of emergency.